HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy

Antivir Ther. 2017;22(4):365-368. doi: 10.3851/IMP3130. Epub 2017 Jan 13.

Abstract

Direct-acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in an HCV-infected patient carrying a recombinant genotype 2k/1b. This strain, first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use
  • Drug Combinations
  • Drug Resistance, Viral / genetics*
  • Female
  • Genotype
  • Hepacivirus / classification
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Hepacivirus / growth & development
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Italy
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / virology
  • Middle Aged
  • Phylogeny
  • Reassortant Viruses / classification
  • Reassortant Viruses / drug effects
  • Reassortant Viruses / genetics*
  • Reassortant Viruses / growth & development
  • Ribavirin / therapeutic use
  • Sequence Analysis, RNA
  • Sofosbuvir / therapeutic use
  • Treatment Failure

Substances

  • Antiviral Agents
  • Drug Combinations
  • Ribavirin
  • Alanine Transaminase
  • Sofosbuvir